checkAd
    Startseite > Aktien > Eyenovia > Nachrichten
    Eyenovia Aktie
    0,7038
     
    USD
    -4,36 %
    -0,0321 USD
    Letzter Kurs 11:37:03 NMS
    0,7359
     
    USD
    300 STK
    Geldkurs 29.05.24
    0,7400
     
    USD
    18.300 STK
    Briefkurs 29.05.24
    ISIN: US30234E1047 · WKN: A2N6DV · SYM: EYEN · USA

    Neueste Nachrichten

    Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
    15.05.24 · globenewswire · Eyenovia
    Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
    14.05.24 · globenewswire · Eyenovia
    Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension
    25.04.24 · globenewswire · Eyenovia
    Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
    08.04.24 · globenewswire · Eyenovia
    Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
    03.04.24 · globenewswire · Eyenovia
    Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
    18.03.24 · globenewswire · Eyenovia
    NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
    13.03.24 · globenewswire · Eyenovia
    Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
    11.03.24 · globenewswire · Eyenovia
    Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
    05.03.24 · globenewswire · Eyenovia
    Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
    13.02.24 · globenewswire · Eyenovia
    Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
    16.01.24 · globenewswire · Eyenovia
    Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
    13.11.23 · globenewswire · Eyenovia